GT Biopharma, Inc. (NASDAQ:GTBP – Get Free Report) was the recipient of a large increase in short interest in the month of October. As of October 15th, there was short interest totalling 10,400 shares, an increase of 108.0% from the September 30th total of 5,000 shares. Currently, 0.5% of the company’s stock are short sold. Based on an average daily volume of 14,500 shares, the short-interest ratio is currently 0.7 days.
GT Biopharma Stock Up 3.3 %
GT Biopharma stock traded up $0.10 during trading on Friday, reaching $3.12. 44,103 shares of the company’s stock were exchanged, compared to its average volume of 433,232. The company’s 50-day moving average is $2.19 and its two-hundred day moving average is $2.82. GT Biopharma has a 52-week low of $1.92 and a 52-week high of $10.66.
GT Biopharma (NASDAQ:GTBP – Get Free Report) last announced its quarterly earnings results on Wednesday, August 14th. The company reported ($2.24) earnings per share for the quarter.
Institutional Trading of GT Biopharma
About GT Biopharma
GT Biopharma, Inc, a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology products based on its proprietary Tri-specific Killer Engager (TriKE) fusion protein immune cell engager technology platform. It develops GTB-3550, a single-chain tri-specific recombinant fusion protein conjugate that is in Phase I clinical trial for the treatment of myelodysplastic syndromes, refractory/relapsed acute myeloid leukemia or advanced systemic mastocytosis, and CD33+ malignancies.
See Also
- Five stocks we like better than GT Biopharma
- How Investors Can Find the Best Cheap Dividend Stocks
- Real Estate Sector Outperforms: 3 Stocks to Gain Exposure
- High Flyers: 3 Natural Gas Stocks for March 2022
- Lam Research Proves Analysts Wrong with a Strong Earnings Report
- 3 Fintech Stocks With Good 2021 Prospects
- PureCycle: Up 250% in 2024 – Is This Materials Stock Still a Buy?
Receive News & Ratings for GT Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GT Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.